The newly organized research project “MELLODDY” (Machine Learning Ledger Orchestration for Drug Discovery), involving ten large pharma companies and seven technology providers, is that kind of deals which can catalyze a transition of the pharmaceutical industry to a new level -- a “paradigm shift”, as one might refer to it in terms of Thomas Kuhn’s “The Structure of Scientific Revolutions”.
The project aims at developing a state-of-the-art platform for collaboration, based on Owkin’s blockchain architecture technology, which would allow collective training of artificial intelligence (AI) algorithms using data from multiple direct pharmaceutical competitors, without exposing their internal know-hows and compromising their intellectual property -- for the collective benefit of everyone involved.
